Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 12,871 Shares

Key Points

• Insider sale: Director Mark Goldsmith sold 12,871 shares on March 17 at an average price of $99.48 for about $1.28M, reducing his stake by 4.44% to 276,698 shares (≈$27.53M).
• Earnings miss and analyst view: Revolution Medicines reported quarterly EPS of ($1.86) versus estimates of ($1.56) and analysts forecast -3.49 EPS for the year, though the consensus rating remains a Buy with a $78.94 target.
• Stock level and ownership: RVMD traded near $99.29 mid-day (52‑week range $29.17–$124.49; 50-day MA $103.58, 200-day MA $76.24) and is heavily institutionally held (94.34%).

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark Goldsmith sold 12,871 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $1,280,407.08. Following the sale, the insider owned 276,698 shares in the company, valued at approximately $27,525,917.04. The trade was a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Revolution Medicines Price Performance

Revolution Medicines stock traded up $1.18 during midday trading on Thursday, hitting $99.29. 1,485,201 shares of the company were exchanged, compared to its average volume of 2,335,170. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $124.49. The company's fifty day moving average price is $103.58 and its 200-day moving average price is $76.24. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the firm posted ($1.12) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines during the 4th quarter worth $32,000. Global Retirement Partners LLC lifted its stake in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock valued at $32,000 after buying an additional 361 shares during the last quarter. Torren Management LLC acquired a new position in shares of Revolution Medicines during the fourth quarter valued at $33,000. Arax Advisory Partners bought a new position in shares of Revolution Medicines during the fourth quarter worth about $38,000. Finally, GAMMA Investing LLC grew its position in shares of Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company's stock worth $39,000 after acquiring an additional 260 shares during the last quarter. Institutional investors own 94.34% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on RVMD shares. Evercore upgraded Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Jefferies Financial Group started coverage on Revolution Medicines in a research note on Monday. They set a "buy" rating for the company. Wedbush reaffirmed an "outperform" rating on shares of Revolution Medicines in a research report on Friday, January 9th. Finally, UBS Group assumed coverage on Revolution Medicines in a research note on Friday, February 27th. They set a "buy" rating for the company. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.